Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.
“Recently, systemic immunotherapy has become the standard of care for many patients with previously treated metastatic urothelial carcinoma,” said Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center in New York. He presented results from the CheckMate 032 trial at the European Society for Medical Oncology (ESMO) 2018 Congress.
The study had three cohorts. In the NIVO3 cohort, 78 patients received nivolumab monotherapy at a dose of 3 mg/kg; 104 patients in the NIVO3+IPI1 cohort received the same nivolumab dose plus ipilimumab 1 mg/kg; and in the NIVO1+IPI3 cohort, 92 patients received nivolumab 1 mg/kg and ipilimumab 3 mg/kg. Previous reports showed response rates of approximately 26% in the first of those two cohorts, with only a preliminary outcome regarding the third.
Source: Cancer Network